193 related articles for article (PubMed ID: 35881112)
1. Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
Miao YR; Thakkar K; Cenik C; Jiang D; Mizuno K; Jia C; Li CG; Zhao H; Diep A; Xu Y; Zhang XE; Yang TTC; Liedtke M; Abidi P; Leung WS; Koong AC; Giaccia AJ
J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35881112
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
[TBL] [Abstract][Full Text] [Related]
3. Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA.
Zheng C; Zhang X; Zhao Z; Hao X; Wei J; Sun J
Protein Pept Lett; 2017; 24(6):489-494. PubMed ID: 28260502
[TBL] [Abstract][Full Text] [Related]
4. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
6. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
7. No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.
Nys J; Smulski CR; Tardivel A; Willen L; Kowalczyk C; Donzé O; Huard B; Hess H; Schneider P
PLoS One; 2013; 8(4):e61350. PubMed ID: 23620746
[TBL] [Abstract][Full Text] [Related]
8. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
Meinl E; Krumbholz M
Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
[TBL] [Abstract][Full Text] [Related]
9. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
[TBL] [Abstract][Full Text] [Related]
10. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
11. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
12. [Cloning, soluble expression and characterization of human sBCMA].
Guan ZB; Cao P; Ye JL; Zhang SQ
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):46-51. PubMed ID: 16572839
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
[TBL] [Abstract][Full Text] [Related]
14. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
15. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
[TBL] [Abstract][Full Text] [Related]
16. BAFF, APRIL and their receptors: structure, function and signaling.
Bossen C; Schneider P
Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.
Maia S; Pelletier M; Ding J; Hsu YM; Sallan SE; Rao SP; Nadler LM; Cardoso AA
PLoS One; 2011; 6(6):e20787. PubMed ID: 21687682
[TBL] [Abstract][Full Text] [Related]
18. Cellular membrane-based vesicles displaying a reconstructed B cell maturation antigen for multiple myeloma therapy by dual targeting APRIL and BAFF.
He C; Zhang M; Liu L; Han Y; Xu Z; Xiong Y; Yan F; Su D; Chen H; Zheng Y; Cheng F
Acta Biomater; 2022 Apr; 143():406-417. PubMed ID: 35218967
[TBL] [Abstract][Full Text] [Related]
19. Engineering an APRIL-specific B cell maturation antigen.
Patel DR; Wallweber HJ; Yin J; Shriver SK; Marsters SA; Gordon NC; Starovasnik MA; Kelley RF
J Biol Chem; 2004 Apr; 279(16):16727-35. PubMed ID: 14764606
[TBL] [Abstract][Full Text] [Related]
20. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
